AIM： As tumor markers for pancreatic carcinoma, carcinoembryonic antigen （CEA） and carbohydrate antigen （CA） 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic...AIM： As tumor markers for pancreatic carcinoma, carcinoembryonic antigen （CEA） and carbohydrate antigen （CA） 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS： A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA （highly specific for pancreatic cancer） and CA 19-9 （highly sensitive for pancreatic cancer）, in 48 patients with pancreatic exocrine tumors. RESULTS： When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone （55%） was higher than that of CEA alone （27%） and the specificity of RCAS1 alone （92%） was greater than that of CA19-9 alone （78%）. When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 （95%） was superior to those of CA19-9 alone （78%）, RCAS1 alone （55%, P = 0.002）, CEA alone （27%） （P〈0.001）, RCAS1 and CEA （59%） and CA19-9 and CEA （82%）. CONCLUSION： These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma.展开更多
目的检测表达在SiSo细胞上的受体结合肿瘤抗原(receptor-binding cancer antigen expressed on SiSo cells,RCASl)在不同肿瘤患者血清及组织中的表达水平,探讨其在肿瘤发生、发展中的作用机制.方法收集肿瘤患者85例(患者组)和健康体检者...目的检测表达在SiSo细胞上的受体结合肿瘤抗原(receptor-binding cancer antigen expressed on SiSo cells,RCASl)在不同肿瘤患者血清及组织中的表达水平,探讨其在肿瘤发生、发展中的作用机制.方法收集肿瘤患者85例(患者组)和健康体检者(对照组)98例,采用免疫组织化学染色方法观察肿瘤组织中RCAS1的表达情况,采用ELISA方法检测受检者血清中RCAS1水平,并对检测结果进行统计学分析.结果免疫组化结果显示RCAS1在肿瘤组织中呈粗颗粒状黄褐色反应产物.患者组RCAS1水平明显高于对照组,差异有统计学意义(P<0.01).鼻咽癌患者组织中RCAS1的阳性表达率为76.2%,且随着病情的加重,血清RCAS1的水平和阳性检出率均不断升高,各组间比较差异均有统计学意义(P<0.01,P<0.05).结论血清RCAS1水平检测可用于肿瘤患者的辅助诊断.展开更多
文摘AIM： As tumor markers for pancreatic carcinoma, carcinoembryonic antigen （CEA） and carbohydrate antigen （CA） 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS： A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA （highly specific for pancreatic cancer） and CA 19-9 （highly sensitive for pancreatic cancer）, in 48 patients with pancreatic exocrine tumors. RESULTS： When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone （55%） was higher than that of CEA alone （27%） and the specificity of RCAS1 alone （92%） was greater than that of CA19-9 alone （78%）. When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 （95%） was superior to those of CA19-9 alone （78%）, RCAS1 alone （55%, P = 0.002）, CEA alone （27%） （P〈0.001）, RCAS1 and CEA （59%） and CA19-9 and CEA （82%）. CONCLUSION： These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma.
文摘目的检测表达在SiSo细胞上的受体结合肿瘤抗原(receptor-binding cancer antigen expressed on SiSo cells,RCASl)在不同肿瘤患者血清及组织中的表达水平,探讨其在肿瘤发生、发展中的作用机制.方法收集肿瘤患者85例(患者组)和健康体检者(对照组)98例,采用免疫组织化学染色方法观察肿瘤组织中RCAS1的表达情况,采用ELISA方法检测受检者血清中RCAS1水平,并对检测结果进行统计学分析.结果免疫组化结果显示RCAS1在肿瘤组织中呈粗颗粒状黄褐色反应产物.患者组RCAS1水平明显高于对照组,差异有统计学意义(P<0.01).鼻咽癌患者组织中RCAS1的阳性表达率为76.2%,且随着病情的加重,血清RCAS1的水平和阳性检出率均不断升高,各组间比较差异均有统计学意义(P<0.01,P<0.05).结论血清RCAS1水平检测可用于肿瘤患者的辅助诊断.
